Recently, the 5th Global Digital Trade Expo was grandly held at the Hangzhou Grand Exhibition Center. Co-hosted by the People's Government of Zhejiang Province and the Ministry of Commerce, and co-organized by the People's Government of Hangzhou, the Department of Commerce of Zhejiang Province, and the Trade Development Bureau of the Ministry of Commerce, the event brought together global industry leaders. JeYou Pharmaceutical's small molecule innovative drug manufacturing base, Zhejiang Hangyu Pharmaceutical Co., Ltd. (hereinafter "Hangyu Pharmaceutical"), made its appearance at this year's Digital Trade Expo, showcasing its commercial manufacturing capabilities in the small molecule innovative drug sector to global clients.

The Global Digital Trade Expo is China's only national-level, international, and specialized exhibition focused on digital trade. This year's expo adopted the annual theme "Meeting the AI Future at the Digital Trade Expo," featuring over 2,000 exhibitors and attracting more than 50,000 professional visitors from 163 countries and regions, including over 12,000 international attendees. With a total exhibition area of 170,000 square meters, the event featured 1 thematic pavilion and 6 specialized industry exhibition zones covering Silk Road E-commerce, Artificial Intelligence, Digital Mobility, Digital Entertainment, Digital Healthcare, and Spatial Intelligence, along with an inaugural Digital Trade Innovation Integration Exhibition Zone.

JeYou Pharmaceutical has established an in-depth presence in innovative drug industrialization, with two pharmaceutical manufacturing bases in Hangzhou, Zhejiang and Wuxi, Jiangsu, covering the production of small molecule and large molecule innovative drugs respectively. Hangyu Pharmaceutical, founded in 2021, is located in the Qiantang Linjiang area of Hangzhou, Zhejiang Province, covering approximately 100 mu (about 6.7 hectares). Its core business focuses on the production of Class 1 small molecule innovative drug formulations, with an annual production capacity of 200 million tablets/capsules of solid dosage forms. The facility has integrated globally advanced pharmaceutical technologies and equipment, building a complete capability chain spanning early-stage clinical sample production, pivotal clinical sample manufacturing, commercial production, and sales, while also providing high-quality CDMO/CMO services for innovative drug formulations to industry clients.

Hangyu Pharmaceutical's appearance at the Digital Trade Expo demonstrated JeYou Pharmaceutical's advanced manufacturing capabilities in the small molecule innovative drug formulation sector, and provided a new practical example of how innovative pharmaceutical companies can leverage digital platforms to connect with global resources. Looking ahead, as JeYou Pharmaceutical's innovative drug pipeline gradually enters its value realization phase, Hangyu Pharmaceutical's production capacity will serve as a critical pillar for product commercialization, while also empowering upstream and downstream collaboration to help build a more resilient innovative pharmaceutical industry ecosystem.

Disclaimer:

1. This information is intended to share company progress and is for reference by healthcare professionals only, not for advertising purposes. For clinical medication, please follow the advice or guidance of physicians or other healthcare professionals and refer to the drug package insert.

2. JeYou Pharmaceutical does not recommend any drug or treatment for any specific use.

About JeYou Pharmaceutical

Shanghai JeYou Pharmaceutical Technology Co., Ltd. focuses on the "3+1" core therapeutic areas of oncology, nephrology, pain, and autoimmune diseases, specializing in the R&D, manufacturing, and commercial translation of innovative drugs. The company has built a differentiated product portfolio with international competitiveness, covering monoclonal/bispecific antibodies, TCE, ADCs, small molecule drugs, and PROTACs, among other modalities. Its current self-developed product portfolio comprises 40+ candidates, with over 10 in clinical stages. In February 2026, the company's self-developed Class 1 anti-tumor innovative drug Jielemei® (suximerex sulfate tablets) was approved for marketing by the National Medical Products Administration.